title: Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma.
abstract: A 55-year-old woman with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia (ATL) and a history of previously treated Strongyloides stercoralis infection received anti-CD52 monoclonal antibody therapy with alemtuzumab on a clinical trial. After an initial response, she developed ocular involvement by ATL. Alemtuzumab was stopped and high-dose corticosteroid therapy was started to palliate her ocular symptoms. Ten days later, the patient developed diarrhea, vomiting, fever, cough, skin rash, and a deteriorating mental status. She was diagnosed with disseminated S. stercoralis. Corticosteroids were discontinued and the patient received anthelmintic therapy with ivermectin and albendazole with complete clinical recovery.
authors.affiliation: Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. stewardo@mail.nih.gov
authors.forename: Donn M
authors.initials: DM
authors.lastname: Stewart
authors.forename: Roshan
authors.initials: R
authors.lastname: Ramanathan
authors.forename: Siddhartha
authors.initials: S
authors.lastname: Mahanty
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Fedorko
authors.forename: John E
authors.initials: JE
authors.lastname: Janik
authors.forename: John C
authors.initials: JC
authors.lastname: Morris
mesh_terms: D000818:Animals; D005260:Female; D015490:HTLV-I Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016399:Lymphoma, T-Cell / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D008875:Middle Aged; D009894:Opportunistic Infections / Q000150:complications* / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology; D012008:Recurrence; D017171:Strongyloides stercoralis / Q000302:isolation & purification*; D013322:Strongyloidiasis / Q000150:complications* / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents